Footnotes

• Competing interests AB, None; WL, None; DS, Received honoraria for speaking and attending advisory boards from Novartis pharmaceuticals. JOW, Scientific advisory board and/or paid lectures and/or recipient of research funding from Danone, Airsonette, UCB pharma, Novartis, Merck, Astra/Zeneka, GSK, Lincoln Medical, Mead Johnson. Until 2009 Trustee of Anaphylaxis Campaign and Editor in Chief of Pediatric Allergy and Immunology. Currently Trustee of RCPCH and member of council. Chair of RCPCH allergy care-pathways project. Contributor to RCPCH feedback to NICE omalizumab HTA for 6–12 year olds.

• Provenance and peer review Commissioned; externally peer reviewed.